Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer

Figure 2

The patient tumors present a feature of histological heterogeneity. (a) Comparative H&E and immunohistochemical pictures of BC across time. Examples of ductal carcinoma (HER2-) from primary tumor biopsy (column on the left), ductal mixed with lobular carcinoma (HER2-/+) from surgical excision tumor (column on the middle), and ductal carcinoma (HER2+) from lymph node biopsy (column on the right) are displayed. Scale bar, 100 μm. (b) The positive rate of immunohistochemistry markers changed throughout time. T1, time point 1, needle core biopsy; T2, time point 2, surgical excision. 1k and 1I, samples from separate tumor locations; T3, time point 3, cervical lymph node biopsy; (c) the table displays the frequency distribution of clinicopathological features at various time stages.

(a)

(b)

(c)